Prenumeration
During 2023 STENOCARE delivered record in gross sales amounting to DKK 6.9m, corresponding to a growth of 18%, in combination with a decreasing cost base. For 2024 we estimate net sales of DKK 16.5m driven by, among other things, new products in Australia and Denmark as well as introduction of the first product in Germany, resulting in a positive EBITDA-result at the end of the year. With estimated net sales of DKK 66.6m by 2026, and with an applied P/S multiple of 5x, a potential present value per share of DKK 8.8 (9.4) is derived in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.
Read more about Analyst Group (Swedish)
This is a press release from Analyst Group regarding the publication of an analysis on STENOCARE. Readers may assume that Analyst Group has received compensation for making the analysis. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.